Thomas Koch, MD, FAAP, FAAN

Slideshows

When evaluating and diagnosing migraines in pediatric patients, a thorough medical history is key to giving a diagnosis. These 8 questions are structured to pinpoint concerning headache patterns earlier in the diagnosing process.

8 questions for a thorough history to diagnose migraines

Medical writing support provided by John Jesitus, MA

A common complaint among children and adolescents, headaches including migraines remain the top reason for referrals to pediatric neurology.

 The worldwide prevalence of migraine in children and adolescents is 7.7%.

 Reported prevalence increases with age, from 3% (age 3 to 7 years) to 8% to 23% (age 11 to 15+ years).

 Approximately 10% of school-aged children suffer from migraine, with boys being more frequently affected before puberty, and girls more frequently thereafter.

 A comprehensive 2010 survey estimated that migraine has a global prevalence of 14.7%, making it the third-most-common disease in the world in men and women.

All these headaches carry costs beyond their physical toll. On average, children with migraine miss 8 school days yearly, versus 4 for children without migraines.

 Among adults globally, migraine ranks seventh among specific causes of disability, and among the top 10 causes of disability in 14 of 21 world regions.

 One analysis reveals that between 2008 and 2013, patients with migraine had significantly higher direct and indirect healthcare costs ($10,363 and $11,294, respectively) than did patients without migraines ($4619 and $8945, respectively).

Additionally, the migraine burden cannot be measured with dollars alone. Researchers have likened the impact of migraines on children's quality of life to that of arthritis, diabetes, and cancer.

Yet the seriousness of migraine remains underappreciated by parents, teachers, primary care providers,12 and often migraine sufferers themselves, most of whom are never diagnosed or treated.

 The psychosocial and economic burden of pediatric migraine, coupled with the relief offered by newer treatments including triptans, lends urgency to accurately identifying and promptly treating migraine.

The considerable variability of migraine within and among patients stems from dysfunction of an ion channel in brainstem nuclei that normally modulates sensory input and regulates the meningeal blood vessels.

 Pathophysiologically, neural abnormalities drive dilation of cranial blood vessels, resulting in further nerve activation and pain.

International Classification of Headache Disorders

, 3rd edition (ICHD-3), classifies headaches into primary, secondary, and those caused by cranial neuropathies and other headaches (Table 1).

This category includes diagnostic criteria for migraine and its variants, along with tension-type headache (TTH) and other trigeminal autonomic cephalalgias (TACs).

Migraines can occur with or without aura; specifically, at least 2 attacks that include 1 or more reversible visual, sensory, or other symptoms that meet specific temporal criteria.

Patients who have migraine without aura may experience prodromal symptoms up to 48 hours before other migraine symptoms. These symptoms may include:

Additional types of primary headaches include TTH and TAC.

All forms of TTH typically involve a mild-to-moderate bilateral headache, pressing or tightening in quality. Increased pericranial tenderness is the most significant abnormal finding in patients with any type of TTH.

 Pain does not worsen with routine physical activity and may or may not be associated with nausea; phonophobia or photophobia may occur.

Finally, TACs are unilateral headaches, usually accompanied by prominent cranial parasympathetic autonomic features (such as conjunctival injection and/or lacrimation, nasal congestion, and facial sweating), which are lateralized and ipsilateral to the headache.

Additional forms of primary headaches include the following (see ICHD-3 for descriptions and details

·      New daily persistent headache (NDPH).

Secondary headaches include new headaches and preexisting or significantly worsening preexisting headaches caused by primary disorders such as trauma and systemic diseases.

·      Trauma or injury to head and/or neck

·      Cranial and/or cervical vascular disorder

·      Nonvascular intracranial disorder

·      Increased intracranial pressure

·      Headache or facial pain attributed to disorder of the cranium, neck, eyes, ears, nose, sinuses, teeth, mouth, or other facial/cranial structure.

Cranial neuropathies, centrofacial pain, and other headaches include painful cranial-nerve lesions and other facial pains deriving from a complex catalog of causes such as trigeminal, glossopharyngeal, occipital, and other neuralgias; optic neuritis; ischemic oculomotor nerve palsy; and various facial neuropathies and syndromes.

Evaluating pediatric migraine requires a systematic approach involving the following steps:

Usually, a thorough headache history provides enough clues for accurate diagnosis.

 Questions (Table 2) are structured to identify more concerning headache patterns early in the process.

Keep in mind that there are red flags that should trigger consideration of neuroimaging for suspicion of intracranial pathology (see “Red flags for considering neuroimaging,” page XX).

This portion of the evaluation should include the following measurements/investigations:

·      Take vital signs (including blood pressure, temperature, signs of hypertension or infection).

·      Measure head circumference, even in older children.

·      Palpate head and neck for sinus, jaw, ocular or temporomandibular joint tenderness, thyromegaly, or nuchal rigidity.

·      Identify trigger points or areas of maximum tenderness to help determine nature of the pain.

·      Check skin for signs of neurocutaneous syndromes, particularly neurofibromatosis and tuberous sclerosis, which are highly associated with intracranial neoplasms.

More than 98% of children with brain tumors who present with headache have objective neurologic findings.21 Look for abnormalities in these areas during the basic neurologic exam:

·      Gait (including tandem gait)

Routine neuroimaging is not indicated in children with recurrent headaches and normal examination. However, physicians should consider neuroimaging if certain warning signs appear:

·      Recent onset of severe headache

·      Change in headache quality or frequency

·      Abnormal neurologic examination

No evidence supports the use of routine laboratory studies, lumbar puncture, or electroencephalogram (EEG) in headache-afflicted children with normal physical and neurologic findings. However, if findings in steps 1 to 3 warrant further exploration, consider appropriate modalities.

Similarly, no evidence supports the use of routine neuroimaging in children with a history of recurring headaches who have a normal neurologic exam. Neuroimaging in children with headaches should be considered when findings in steps 1 to 3 warrant further investigation.

 More specifically, when the neurologic exam is abnormal, when other simultaneous neurologic concerns such as seizures are present, or when headache historical factors such as first, worst, or marked change in headache pattern are reported, neuroimaging should be considered. When considering neuroimaging, magnetic resonance imaging (MRI) would be the preferred imaging modality unless there is a concern for an acute or life-threatening etiology that warrants quick imaging such as computed tomography (CT).

Treatment of pediatric migraines requires a multitiered approach (Table 3), which tailors an individualized treatment plan to each patient's headache pattern and lifestyle and that can accommodate changes if needed.22 Headache frequency may spontaneously increase, for example, and patients may require higher or lower doses than for previous headaches, or, for more difficult headaches, combination therapy. Each child's degree of headache burden should determine how aggressively one treats and manages his or her headaches, considering the following factors:

·      Headache frequency, duration and intensity;

·      Patient's functional disability and pain tolerance;

·      Patient's comorbidities; and

Many patients with moderate-to-severe migraine respond well to oral treatment with analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) administered at the time of an attack (acute/abortive treatment; Table 4). Patients must be educated and able to use their medication as early during the headache as possible. This requires ready access to medications in school, home, and social situations:

 Patients also must avoid medication overuse, a known cause of headaches, by limiting analgesic and NSAID use to 2 to 3 days or less weekly. Keeping a headache diary can track drug use patterns.

Additional agents require caution. For example, aspirin-butalbital-caffeine is frequently prescribed for adult headaches, although, like other aspirin-containing products, it should be avoided in children aged younger than 16 years due to the risk of Reye syndrome.24 Always avoid opiates and other narcotics in children.

Physicians typically reserve serotonin 5-HT

) for moderate-to-severe headaches unresponsive to over-the-counter analgesic therapy.

 Unlike ergot derivatives, triptans offer selective activity, along with well-established dosing regimens, safety, and tolerability.

 Sumatriptan, almotriptan, zolmitriptan, and rizatriptan have earned US Food and Drug Administration (FDA) approval for acute pediatric migraine.

 receptor that has been implicated in the pathophysiology of migraine, and, to a lesser degree, other 5-HT receptors.

 They do this through 3 main mechanisms of action:

·      Peripheral trigeminal inhibition; and

·      Inhibition of transmission through second-order neurons of the trigeminal cervical complex.

In 2006, the FDA warned consumers that taking triptans with selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) could raise users' risk of life-threatening serotonin syndrome. However, careful review of the available evidence has shown that this is not the case.

Experts have suggested guidelines for triptan use in pediatric migraine (Table 6).

 Adverse effects of triptan generally last less than 30 minutes.

With few medications approved for pediatric migraine, physicians frequently prescribe drugs used for migraine in adults (Table 7

Articles

Physicians must understand current diagnostic criteria for pediatric migraine and its variants, and exercise their best clinical judgment regarding treatment.

Thomas Koch, MD, FAAP, FAAN

Articles

8 questions for a thorough history to diagnose migraines

Pediatric migraine: Diagnostic criteria and treatment